Pharvaris is a clinical-stage biomedical company focused on bringing oral bradykinin B2-receptor antagonists to patients.
Pharvaris has raised $132.3M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.
Pharvaris's investors include General Atlantic, Cormorant Asset Management, Venrock, Foresite Capital, Bain Capital Life Sciences.
Pharvaris is headquartered in Zug, Switzerland.
Pharvaris is a clinical-stage biomedical company focused on bringing oral bradykinin B2-receptor antagonists to patients.
Pharvaris is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Pharvaris — Funding & Investors." VCBacked, May 8, 2026, https://www.vcbacked.co/company/pharvaris. Accessed July 19, 2026.
VCBacked. (2026). Pharvaris — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/pharvaris
{{cite web |title=Pharvaris — Funding & Investors |url=https://www.vcbacked.co/company/pharvaris |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated